Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis

Schizophrenia Research

Volumn 141, Issue 1, 2012, Pages 78-82

  Faridi, Kia ^a,b,c   Joober, Ridha ^a,b,c   Malla, Ashok ^a,b,c  

^a Prevention and Early Intervention Program for Psychosis   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

Cannabis; First episode psychosis; Marijuana; Medication adherence; Schizophrenia; Treatment outcome

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DSM-IV; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SYMPTOM;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MEDICATION ADHERENCE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84865998027     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.07.023     Document Type: Article

References (31)

1. Addington J., Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr. Scand. 2007, 115(4):304-309.
2. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 1992, 6(3):201-208.
3. Archie S., Rush B.R., Akhtar-Danesh N., Norman R., Malla A., Roy P., Zipursky R.B. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophr. Bull. 2007, 33(6):1354-1363.
4. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325(7374):1212-1213.
5. Baeza I., Graell M., Moreno D., Castro-Fornieles J., Parellada M., Gonz·lez-Pinto A., Pay B., Soutullo C., de la Serna E., Arango C. Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). Schizophr. Res. 2009, 113(2-3):129-137.
6. Barnett J.H., Werners U., Secher S.M., Hill K.E., Brazil R., Masson K.I.M., Pernet D.E., Kirkbride J.B., Murray G.K., Bullmore E.T., Jones P.B. Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry 2007, 190(6):515-520.
7. Cantwell R., Brewin J., Glazebrook C., Dalkin T., Fox R., Medley I., Harrison G. Prevalence of substance misuse in first-episode psychosis. Br. J. Psychiatry 1999, 174(2):150-153.
8. Cassidy C.M., Schmitz N., Malla A. Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis. CJP 2008, 53(1):26-33.
9. Cassidy C.M., Rabinovitch M., Schmitz N., Joober R., Malla A. A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis. J. Clin. Psychopharmacol. 2010, 30(1):64-67. 10.1097/JCP.1090b1013e3181ca1003df.
10. Coldham E.L., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr. Scand. 2002, 106(4):286-290.
11. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 2005, 57(6):594-608.
12. D'Souza D.C., Braley G., Blaise R., Vendetti M., Oliver S., Pittman B., Ranganathan M., Bhakta S., Zimolo Z., Cooper T., Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2008, 198(4):587-603.
13. Gonzalez-Pinto A., Alberich S., Barbeito S., Gutierrez M., Vega P., Ibanez B., Haidar M.K., Vieta E., Arango C. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr. Bull. 2011, 37(3):631-639.
14. Grech A., Van Os J., Jones P.B., Lewis S.W., Murray R.M. Cannabis use and outcome of recent onset psychosis. Eur. Psychiatry 2005, 20(4):349-353.
15. Harrison I., Joyce E.M., Mutsatsa S.H., Hutton S.B., Huddy V., Kapasi M., Barnes T.R.E. Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol. Med. 2008, 38(1):79-88.
16. Henquet C., van Os J., Kuepper R., Delespaul P., Smits M., Campo J.À., Myin-Germeys I. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br. J. Psychiatry 2010, 196(6):447-453.
17. Hides L., Dawe S., Kavanagh D.J., Young R.M. Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. Br. J. Psychiatry 2006, 189(2):137-143.
18. Hinton M., Edwards J., Elkins K., Harrigan S.M., Donovan K., Purcell R., McGorry P.D. Reductions in cannabis and other illicit substance use between treatment entry and early recovery in patients with first-episode psychosis. Early Interv. Psychiatry 2007, 1(3):259-266.
19. Hunt G.E., Bergen J., Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr. Res. 2002, 54(3):253-264.
20. Kao Y.-C., Liu Y.-P. Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC Psychiatry 2010, 10(1):1-11.
21. Kay S.R., Flszbein A., Opfer L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
22. Kuepper R., Morrison P.D., van Os J., Murray R.M., Kenis G., Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr. Res. 2010, 121(1-3):107-117.
23. Levy E., Pawliuk N., Joober R., Abadi S., Malla A. Medication-adherent first-episode psychosis patients also relapse: why?. Can. J. Psychiatry 2012, 57(2):78-84.
24. Malla A., Norman R., McLean T., Scholten D., Townsend L. A Canadian programme for early intervention in non-affective psychotic disorders. Aust. N. Z. J. Psychiatry 2003, 37(4):407-413.
25. Malla A., Norman R., Schmitz N., Manchanda R., Bechard-Evans L., Takhar J., Haricharan R. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol. Med. 2006, 36(05):649-658.
26. Malla A., Norman R., Bechard-Evans L., Schmitz N., Manchanda R., Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol. Med. 2008, 38(11):1585-1593.
27. Mastrigt S., Addington J., Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39(1):69-72.
28. Rabinovitch Mark, Bechard-Evans Laura, Schmitz Norbert, Joober Ridha, Malla Ashok Early Predictors of Nonadherence to Antipsychotic Therapy in First-episode Psychosis 2009, Canadian Psychiatric Association, Ottawa, ON, Canada.
29. Skinner H.A. The drug abuse screening test. Addict. Behav. 1982, 7(4):363-371.
30. Wade D., Harrigan S., Edwards J., Burgess P.M., Whelan G., McGorry P.D. Substance misuse in first-episode psychosis: 15-Month prospective follow-up study. Br. J. Psychiatry 2006, 189:229-234. (SEP.).
31. Zammit S., Moore T.H.M., Lingford-Hughes A., Barnes T.R.E., Jones P.B., Burke M., Lewis G. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br. J. Psychiatry 2008, 193(5):357-363.